Journal
FRONTIERS IN ONCOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2023.1141876
Keywords
non-small cell lung cancer; BRAF mutation; BRAF mutation V600; non-V600 mutation; lung cancer
Categories
Ask authors/readers for more resources
Lung cancer is a leading cause of cancer-related deaths, with non-small cell lung cancer accounting for 85% of cases. The study of genetic alterations has led to targeted therapeutic interventions, including drugs targeting mutations in genes like KRAS, EGFR, BRAF, and ALK. This article summarizes BRAF mutations, available drug therapies, resistance mechanisms, the significance of profiling concurrent mutations, and the role of immune checkpoint inhibitors in BRAF-mutated non-small cell lung cancer.
Lung cancer is the leading cause of cancer related deaths. Among the two broad types of lung cancer, non-small cell lung cancer accounts for 85% of the cases. The study of the genetic alteration has facilitated the development of targeted therapeutic interventions. Some of the molecular alterations which are important targets for drug therapy include Kirsten rat sarcoma (KRAS), Epidermal Growth Factor Receptor (EGFR), V-RAF murine sarcoma viral oncogene homolog B (BRAF), anaplastic lymphoma kinase gene (ALK). In the setting of extensive on-going clinical trials, it is imperative to periodically review the advancements and the newer drug therapies being available. Among all mutations, BRAF mutation is common with incidence being 8% overall and 1.5 - 4% in NSCLC. Here, we have summarized the BRAF mutation types and reviewed the various drug therapy available - for both V600 and nonV600 group; the mechanism of resistance to BRAF inhibitors and strategies to overcome it; the significance of comprehensive profiling of concurrent mutations, and the role of immune checkpoint inhibitor in BRAF mutated NSCLC. We have also included the currently ongoing clinical trials and recent advancements including combination therapy that would play a role in improving the overall survival and outcome of NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available